Methylphenidate (Ritalin)

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• US DEA: Methylphenidate (Ritalin/Concerta) — Schedule II Classification, ADHD FDA Approval, Mechanism vs. Amphetamine (Reuptake Inhibitor vs. Releaser), Lower Abuse Liability at Therapeutic Doses, and College Campus Diversion (2022) REGULATORY · 2022
• US FDA: Methylphenidate (Ritalin, Concerta, Focalin, Daytrana) — Prescribing Information, Pediatric Growth and Cardiovascular Monitoring, Long-Term Neurological Safety Data, Overdose Management, and Extended-Release Formulation Differences (2022) REGULATORY · 2022
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• where to look Hazardous Substances Data Bank (HSDB), as recorded by PubChem (Experimental Properties, CID 4158; where-to-look, not a source of this value) DATABASE · 2026
• EPA CompTox CTX API: predicted properties for DTXSID5023299 (Methylphenidate (Ritalin)) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.